June 20, 2024

A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

• Are you 18-70 years of age living with HIV, and want to be a part of a curative study?
• Is your viral load suppressed/undetectable?
• Are you able to receive an infusion or injection?
• Are you generally healthy?
• Are you willing to temporarily stop taking antiretrovirals?

You may qualify for a HIV treatment study looking at an investigational way to effectively clear the HIV virus in areas of the body that standard antiretroviral treatment is unable to reach. You will receive one of two potential intervention methods. One intervention method is a broadly neutralizing antibody that is given to control growth of the HIV virus and to increase the body’s immune system response. The second intervention method is an injection (IL-15 Superagonist) designed to awaken the immune system, activate any dormant HIV virus, and then kill the virus. The duration of this study is approximately 84-112 weeks pending on which intervention method you receive. There is compensation at each study visit for time and travel.


Contact: If interested, please email kspraggins@uabmc.edu or call 205-934-9346